David-Alexandre C. Gros

David-Alexandre C. Gros, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Eledon Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. We count 7 filings; the first trade dates from 22 February 2016 and the latest from 31 July 2026.

On the market, this insider has only ever bought: 5 purchases, €105k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants.

The median purchase comes to €20k. Clusters matter here: 2 out of 5 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 4 August 2026 with a share grant in Eledon Pharmaceuticals, Inc. The last insider purchase was made public on 21 December 2021, 1,768 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.